Section Arrow
ETNB.NASDAQ
- 89bio
Quotes are at least 15-min delayed:2024/05/17 14:52 EDT
Last
 8.6909
-0.2791 (-3.11%)
Day High 
9.06 
Prev. Close
8.97 
1-M High
9.83 
Volume 
257.78K 
Bid
8.69
Ask
8.7
Day Low
8.69 
Open
9.06 
1-M Low
8.04 
Market Cap 
882.50M 
Currency USD 
P/E -- 
%Yield
10-SMA 9.1 
20-SMA 8.9 
50-SMA 10.32 
52-W High 22.93 
52-W Low 6.575 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-2.00/-2.50
Enterprise Value
909.12M
Balance Sheet
Book Value Per Share
5.19
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
NBYNovaBay Pharmaceuticals0.13+0.01+8.33%-- 
SCPXScorpius Holdings0.1097+0.0096+9.59%-- 
DNAGinkgo Bioworks Holdings0.8056-0.0334-3.98%-- 
JAGXJaguar Health0.265-0.0217-7.57%-- 
ONCOOnconetix0.155+0.014+9.93%-- 
Quotes are at least 15-min delayed:2024/05/17 14:52 EDT
Industry overview quotes are at least 15 minutes delayed
Business Description
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.